SCM Pharma’s new contract manufacturing facility in Northeast England has received approval for commercial production following a successful inspection from the Medicines and Healthcare products Regulatory Agency (MHRA). The company will use its new 26,000-sq.-ft. site for the supply of licensed commercial products and to complement its nearby clinical manufacturing facility for projects requiring scale-up.
 
The site’s capabilities include: highly potent, flammable and toxic products, along with controlled drugs, and houses technology for aseptic filling and terminal sterilization, and is equipped for ampoule filling, vial filling and syringe filling.
 
Dianne Sharp, managing director at SCM Pharma, said, “The official MHRA approval of our new facility is a huge landmark in the history of our company and heralds in a new era for our team. I’d like to thank all those involved in the planning, design and construction of SCM Newburn as the end result is what I believe to be one of the finest contract manufacturing facility of its type in Europe. We are planning an event to officially open the doors this summer before Newburn becomes a hub for the production and supply of licensed drug products to help patients across the world.”